A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
Launched by ELI LILLY AND COMPANY ยท
Trial Information
Current as of September 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medicine called LY4064912 to see how well people tolerate it and what side effects it might have. The study includes both healthy individuals and those who are overweight or have obesity. The medicine will be given either as an injection under the skin or through a small tube placed in a vein in the arm. Researchers will also do blood tests to understand how the body handles the medicine and how the medicine affects the body.
People between the ages of about 18 and 74, of any gender, who are healthy or have overweight or obesity might be eligible to join the study. Participants can expect to receive the study drug and have regular blood tests during the trial. This study is still recruiting volunteers, so if you fit the age and health criteria and are interested, you may want to talk to your doctor or the study team to learn more.
Gender
ALL
Eligibility criteria
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported